• 1
    Fleischer A, Ghadiri A, Dessauge F, Duhamel M, Rebollo MP, Alvarez-Franco F, Rebollo A. Modulating apoptosis as a target for effective therapy. Mol Immunol 2006; 43: 106579.
  • 2
    Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995; 5: 8494.
  • 3
    Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 92122.
  • 4
    Chi SW, Lee SH, Kim DH, Ahn MJ, Kim JS, Woo JY, Torizawa T, Kainosho M, Han KH. Structural details on mdm2-p53 interaction. J Biol Chem 2005; 280: 38795802.
  • 5
    Picksley SM, Spicer JF, Barnes DM, Lane DP. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol 1996; 35: 42934.
  • 6
    Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C, Hochkeppel HK, Lane DP. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13: 21417.
  • 7
    Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L, Wasylyk B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18: 192134.
  • 8
    Chene P, Fuchs J, Carena I, Furet P, Garcia-Echeverria C. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 2002; 529: 2937.
  • 9
    Garcia-Echeverria C, Furet P, Chene P. Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. Bioorg Med Chem Lett 2001; 11: 21614.
  • 10
    Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002; 120: 13416.
  • 11
    Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 8448.
  • 12
    Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser I, Robinson P, Brandt-Rauf PW, Michl J, Fine RL et al. Peptides from the amino terminal mdm-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98: 1243843.
  • 13
    Do TN, Rosal RV, Drew L, Raffo AJ, Michl J, Pincus MR, Friedman FK, Petrylak DP, Cassai N, Szmulewicz J, Sidhu G, Fine RL et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the mdm-2 binding site. Oncogene 2003; 22: 143144.
  • 14
    Rosal R, Pincus MR, Brandt-Rauf PW, Fine RL, Michl J, Wang H. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry 2004; 43: 1754861.
  • 15
    Rosal R, Brandt-Rauf PW, Pincus MR, Wang H, Mao Y, Fine RL. The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev 2005; 57: 65360.
  • 16
    Bao LY, Thelmo WL, Somnay S, Madahar C, Michl J. Characterization of an acinar cell line, BMRPA. 430, derived from adult rat pancreas. FASEB J 1994; 8: 64A.
  • 17
    Bradu S. An in vitro model of pancreatic carcinogenesis: characterization of transformation-associated biological and molecular alterations induced by the tobacco smoke carcinogen NNK in rat pancreatic BMRPA1 cells. Doctoral dissertation, SUNY Downstate Medical Center. 1999.
  • 18
    Nam J, Raffaniello RD, Lin J, Bao LY, Michl J, Raufman J-P. Protein kinase C isoform expression and function in transformed and non-transformed pancreatic acinar cell lines. Biochem Biophys Res Commun 1998; 246: 16671.
  • 19
    Michl J, Ohlbaum D, Silverstein SC. 2-Deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages. II. Dissociation of the inhibitory effects of 2-deoxyglucose on phagocytosis and ATP generation. J Exp Med 1976; 144: 148493.
  • 20
    Corbett T, Polin L, Roberts BJ, Lawson AJ, Leopold WR, White K, Kushner J, Paluch J, Hazeldine S, Moore R, Rake J, Horwitz JP. Transplantable syngeneic rodent tumors. In: TeicherBA, ed. Tumor models in cancer research. Totowa, NJ: Humana Press, 2002. 4171.
  • 21
    Lovell DP. Variation in pentobarbital sleeping time in mice. 2. Variables affecting test results. Lab Anim 1986; 20: 916.
  • 22
    Munro BH. Statistical methods for health care research. Philadelphia, PA: J.B. Lippincott, 1986.
  • 23
    Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower, WR,Jr. Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004; 34: 67482.
  • 24
    Kikuchi Y, Kita T, Hirata J, Sasa H, Nagata I, Fukushima M. Adjuvant effects of antineplastic prostoglandins to cisplatin in nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 1992; 118: 4537.
  • 25
    Roodman GD, Johnson RA, Clibon U. Tumor necorsis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol 1989; 271: 18596.